IM in the deltoid region Female ≥15 yr Three 0.5-mL doses at 0, 1, 6 mth. 2nd dose can be administered between 1 & 2.5 mth after the 1st dose. 3rd dose between 5 & 12 mth after the 1st dose; 9-14 yr Two doses each of 0.5 mL. 2nd dose given between 5 & 13 mth after the 1st dose (if the 2nd dose is administered before the 5th mth after the 1st dose, a 3rd dose should always be administered).
Do not administer intravascularly or intradermally. Syncope (fainting) may occur. Postpone vaccination in patients w/ acute severe febrile illness. Patients w/ thrombocytopenia or any coagulation disorder; impaired immune responsiveness or receiving immunosuppressive treatment. A protective immune response may not be elicited in all vaccinees. Do not use for the prevention of HPV-related lesion progression at the time of vaccination. Postpone vaccination until completion of pregnancy in women who are pregnant or trying to become pregnant. Lactation.
If to be given at the same time as other vaccines, the products should be administered at different sites. Adequate response may not be elicited w/ immunosuppressants.
Sign Out
0a89d684-51a3-43b3-ae18-afbf007aeab6.GIF)
